Shuo Ma1, Steven T Rosen. 1. Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA.
Abstract
PURPOSE OF REVIEW: Enzastaurin - a novel oral antitumor agent that selectively inhibits protein kinase Cbeta activity - has demonstrated promise in phase I and II trials in various advanced cancers, and is being investigated in multiple hematologic malignancies and solid tumors. RECENT FINDINGS: Enzastaurin (LY317615) was initially developed as an antiangiogenic cancer therapy. Subsequent preclinical studies showed its antitumor effect by inhibiting tumor proliferation and inducing apoptosis on multiple cancer cell lines as well as xenograft models. Enzastaurin not only inhibits protein kinase Cbeta activity but also suppresses signaling through the phosphoinositide-3 kinase/AKT pathway. Based on the phase I study, 525 mg/day is the recommended dose for oral enzastaurin. It is well tolerated at this dose, with no clinically significant grade 3 or 4 toxicities. A recent phase II study of enzastaurin in patients with relapsed or refractory diffuse large B-cell lymphoma showed enzastaurin to be associated with prolonged freedom from progression. Several preliminary studies showed promising results in patients with various advanced cancers and suggested that enzastaurin can be safely used long term in combination with traditional chemotherapies. SUMMARY: Enzastaurin is emerging as a promising new antitumor treatment. This review addresses the mechanism of action, development, preclinical studies, and clinical study results with enzastaurin.
PURPOSE OF REVIEW: Enzastaurin - a novel oral antitumor agent that selectively inhibits protein kinase Cbeta activity - has demonstrated promise in phase I and II trials in various advanced cancers, and is being investigated in multiple hematologic malignancies and solid tumors. RECENT FINDINGS:Enzastaurin (LY317615) was initially developed as an antiangiogenic cancer therapy. Subsequent preclinical studies showed its antitumor effect by inhibiting tumor proliferation and inducing apoptosis on multiple cancer cell lines as well as xenograft models. Enzastaurin not only inhibits protein kinase Cbeta activity but also suppresses signaling through the phosphoinositide-3 kinase/AKT pathway. Based on the phase I study, 525 mg/day is the recommended dose for oral enzastaurin. It is well tolerated at this dose, with no clinically significant grade 3 or 4 toxicities. A recent phase II study of enzastaurin in patients with relapsed or refractory diffuse large B-cell lymphoma showed enzastaurin to be associated with prolonged freedom from progression. Several preliminary studies showed promising results in patients with various advanced cancers and suggested that enzastaurin can be safely used long term in combination with traditional chemotherapies. SUMMARY:Enzastaurin is emerging as a promising new antitumor treatment. This review addresses the mechanism of action, development, preclinical studies, and clinical study results with enzastaurin.
Authors: Peter P Ruvolo; Liran Zhou; Julie C Watt; Vivian R Ruvolo; Jared K Burks; Tilahun Jiffar; Steven Kornblau; Marina Konopleva; Michael Andreeff Journal: J Cell Biochem Date: 2011-06 Impact factor: 4.429
Authors: Tobias V Lanz; Simon Becker; Matthias Osswald; Stefan Bittner; Michael K Schuhmann; Christiane A Opitz; Sadanand Gaikwad; Benedikt Wiestler; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Simeon Iwantscheff; Carl Grabitz; Michel Mittelbronn; Andreas von Deimling; Frank Winkler; Sven G Meuth; Wolfgang Wick; Michael Platten Journal: Proc Natl Acad Sci U S A Date: 2013-08-19 Impact factor: 11.205
Authors: Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482
Authors: Lindsay B Kilburn; Mehmet Kocak; Rodney L Decker; Cynthia Wetmore; Murali Chintagumpala; Jack Su; Stewart Goldman; Anuradha Banerjee; Richard Gilbertson; Maryam Fouladi; Larry Kun; James M Boyett; Susan M Blaney Journal: Neuro Oncol Date: 2014-11-27 Impact factor: 12.300
Authors: Lida Mina; Ian Krop; Robin T Zon; Steven J Isakoff; Charles J Schneider; Menggang Yu; Cindy Johnson; LaTrice G Vaughn; Yanping Wang; Maria Hristova-Kazmierski; Oluwatoyin O Shonukan; George W Sledge; Kathy D Miller Journal: Invest New Drugs Date: 2009-02-13 Impact factor: 3.850
Authors: K A Benhadji; M Serova; A Ghoul; E Cvitkovic; C Le Tourneau; S M Ogbourne; F Lokiec; F Calvo; P Hammel; S Faivre; E Raymond Journal: Br J Cancer Date: 2008-12-02 Impact factor: 7.640